Chimerix June 15th Short Interest Update

Chimerix (NASDAQ:CMRX) has shown a rise of 4% or 187,891 shares in the short positions. The bets have increased to 4,934,651 shares on June 15,2016 from 4,746,760 shares on May 31,2016. With respect to the floated shares, the shorts are 12.3%. The days to cover are calculated to be 5, using the standard per day volume of 952,387 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Chimerix (NASDAQ:CMRX): The stock opened at $3.60 on Friday but the bulls could not build on the opening and the stock topped out at $3.74 for the day. The stock traded down to $3.57 during the day, due to lack of any buying support eventually closed down at $3.73 with a loss of -1.58% for the day. The stock had closed at $3.79 on the previous day. The total traded volume was 2,136,795 shares.

The company shares have dropped -91.67% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $58.04 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $4.48 and the 200 Day Moving Average price is recorded at $8.65.

Stocks of Chimerix (NASDAQ:CMRX) rallied by 0.27% during the past week but lost 22.13% on a 4-week basis. The company has outperformed the S&P 500 by 1.93% in the past week but underperformed the index by 19.77% in the last 4 weeks.

Chimerix, Inc. a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Companys lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. In addition, it has an active discovery program focusing on viral targets. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir, marketed under the brand name Viread and in multiple fixed-dose combinations, is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus (CMV).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.